TopoTarget announces new CEO to prepare commercialisation of belinostat
Dr. Francois Martelet has a solid late-stage development and commercialisation experience from the international pharmaceutical industry, including Merck & Co., Novartis, Schering-Plough, Eli Lilly and Roche. During his time with Merck & Co. (2005-2007), he was Vice President & Worldwide Franchise Head, Oncology, from which position he has gained in-depth knowledge of the HDACi drug class via his role in the global launch of Zolinza®. More recently (2007-2009), he was President & CEO of , AVAX Technologies, Inc., a US biotech company which is specialised in cancer vaccines therapy. Francois Martelet is a bilingual English/French speaker, and commands both German and Swedish. He holds a doctorate with distinction in medicine and a masters degree in business (from the Dijon University of Medicine, Dijon, France), and a degree in legal medicine (Descartes University of Medicine, Paris, France). In addition, he has attended advanced management development programs at both Harvard Business School and INSEAD. Francois Martelet is a French national and 50 years old.
The change of responsibilities will take place with immediate effect. In order to ensure a successful transition, Professor Peter Buhl Jensen will, on a fulltime consultative basis, be available for TopoTarget for a six months period in order to facilitate a satisfactory transfer of knowledge.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.